We are live on
!
Find out more
Federated Hermes Portfolio holdings
AUM
$69.6B
1-Year Est. Return
42.52%
This Fund
S&P 500
This Quarter
Est. Return
+1.34%
1 Year Est. Return
+42.52%
3 Year Est. Return
+132.48%
5 Year Est. Return
+152.58%
10 Year Est. Return
+652.43%
AUM
$42.2B
AUM Growth
-$1.23B
(-2.8%)
Cap. Flow
-$952M
Cap. Flow
% of AUM
-2.26%
Top 10 Holdings %
Top 10 Hldgs %
14.57%
Holding
2,171
New
150
Increased
772
Reduced
960
Closed
152
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$156M |
| 2 |
Prologis
PLD
|
+$150M |
| 3 |
Chevron
CVX
|
+$109M |
| 4 |
Qualcomm
QCOM
|
+$101M |
| 5 |
Paycom
PAYC
|
+$90.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
FUSN
Fusion Pharmaceuticals Inc. Common Shares
FUSN
|
+$230M |
| 2 |
Kimberly-Clark
KMB
|
+$160M |
| 3 |
Stanley Black & Decker
SWK
|
+$130M |
| 4 |
Paychex
PAYX
|
+$113M |
| 5 |
Dominion Energy
D
|
+$105M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 18.81% |
| 2 | Healthcare | 17.11% |
| 3 | Financials | 12.73% |
| 4 | Industrials | 9.87% |
| 5 | Consumer Discretionary | 9.74% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
276
Oracle
ORCL
$404B
| $36.4M | 0.09% |
257,573
+207,340
| +413% | +$25.7M |
|
277
Home Depot
HD
$305B
| $36.2M | 0.09% |
105,079
+14,190
| +16% | +$4.84M |
|
278
Tetra Tech
TTEK
$9.4B
| $35.3M | 0.08% |
864,240
-85,800
| -9% | -$3.5M |
|
279
ConocoPhillips
COP
$170B
| $35.3M | 0.08% |
308,530
-9,153
| -3% | -$1.11M |
|
280
Align Technology
ALGN
$10.4B
| $35.3M | 0.08% |
146,088
+40,423
| +38% | +$11.3M |
|
|
CFLT
281
DELISTED
Confluent
CFLT
| $34.3M | 0.08% |
1,160,770
+19,170
| +2% | +$551K |
|
282
General Motors
GM
$74.9B
| $34.2M | 0.08% |
737,086
+2,758
| +0.4% | +$125K |
|
283
Hubbell
HUBB
$23.2B
| $34.1M | 0.08% |
93,292
-1,322
| -1% | -$518K |
|
|
MORF
284
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $33.9M | 0.08% |
995,000
| – | – |
|
285
Telus
TU
$14.3B
| $33.6M | 0.08% |
2,216,405
-156,932
| -7% | -$2.53M |
|
286
Ross Stores
ROST
$72.3B
| $33M | 0.08% |
227,352
+58,354
| +35% | +$8.07M |
|
287
TD Synnex
SNX
$21B
| $32.9M | 0.08% |
284,698
+67,148
| +31% | +$8.2M |
|
288
Community Bank
CBU
$3.3B
| $32.7M | 0.08% |
691,879
+44,137
| +7% | +$2M |
|
289
Zoom
ZM
$27.2B
| $32.5M | 0.08% |
548,969
+39,748
| +8% | +$2.44M |
|
290
Rockwell Automation
ROK
$46.3B
| $32.2M | 0.08% |
116,836
+10,701
| +10% | +$2.89M |
|
|
WBTN
291
WEBTOON Entertainment Inc
WBTN
$1.47B
| $32.1M | 0.08% |
+1,408,000
| New | +$32.3M |
|
292
Interactive Brokers
IBKR
$40.2B
| $32.1M | 0.08% |
1,048,648
+7,508
| +0.7% | +$224K |
|
293
Vaxcyte
PCVX
$8.81B
| $32.1M | 0.08% |
425,640
-110
| -0% | -$7.49K |
|
294
Ryan Specialty Holdings
RYAN
$4.79B
| $32M | 0.08% |
552,742
+101,022
| +22% | +$5.39M |
|
295
Dutch Bros
BROS
$5.79B
| $31.9M | 0.08% |
771,200
+371,200
| +93% | +$12.8M |
|
296
Northern Trust
NTRS
$32.7B
| $31.9M | 0.08% |
379,330
+123,720
| +48% | +$10.4M |
|
297
IBM
IBM
$234B
| $31.7M | 0.08% |
183,544
+52,385
| +40% | +$9.1M |
|
|
ANSS
298
DELISTED
Ansys
ANSS
| $31.6M | 0.08% |
98,399
-4,171
| -4% | -$1.37M |
|
299
nVent Electric
NVT
$23.8B
| $31.5M | 0.07% |
410,902
+25,482
| +7% | +$1.98M |
|
300
Linde
LIN
$213B
| $31.4M | 0.07% |
71,549
+4,805
| +7% | +$2.11M |
|
Similar funds
Federated Hermes's Q2 2024 Portfolio in Review
As of Q2 2024, Federated Hermes held 2,171 positions worth $42.2B, down 2.8% from $43.4B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
Federated Hermes's Q2 2024 filing shows 150 new, 772 increased, 960 reduced and 152 closed positions. Its largest new stake was Loar Holdings: 729,296 shares worth $39M. The largest sale was Fusion Pharmaceuticals Inc. Common Shares, an estimated $230M.
By sector, the portfolio is most concentrated in Technology at 19% of assets, up from 17% a quarter earlier, followed by Healthcare and Financials.
- Federated Hermes's largest Q2 2024 buy was Loar Holdings: 729,296 shares worth $39M.
- Federated Hermes added most to Bristol-Myers Squibb in Q2 2024, an estimated $156M increase.
- Federated Hermes's biggest Q2 2024 reduction was Kimberly-Clark, cutting an estimated $160M.
- Federated Hermes fully exited Fusion Pharmaceuticals Inc. Common Shares in Q2 2024, selling an estimated $230M.
- Federated Hermes's ten largest holdings make up 15% of its $42.2B portfolio in Q2 2024.
- Federated Hermes opened 150 new positions and closed 152 in Q2 2024.
- Federated Hermes's portfolio value fell 2.8% quarter-over-quarter to $42.2B.
Based on Federated Hermes's 13F filing for Q2 2024, filed 8 Aug 2024.